Lakeshore Biopharma CO., LTD. (LSBWF) — SEC Filings

Overview

Lakeshore Biopharma CO., LTD. (LSBWF) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Nov 4, 2025: LakeShore Biopharma Co., Ltd. (formerly YS Biopharma Co., Ltd. and YishengBio Co., Ltd.) filed a 6-K report on November 4, 2025. The filing includes a press release announcing a definitive agreement for the company to go private. The company's principal executive offices are located in Beijing, PRC.

Sentiment Summary

Across 47 filings, the sentiment breakdown is: 5 bullish, 3 bearish, 36 neutral, 3 mixed. The dominant filing sentiment for Lakeshore Biopharma CO., LTD. is neutral.

Filing Type Overview

Lakeshore Biopharma CO., LTD. (LSBWF) has filed 43 6-K, 2 20-F, 1 SC 13G/A, 1 SC 13G with the SEC between Jan 2024 to Nov 2025.

Filings by Year

2025 · 2024

Recent Filings (47)

• LakeShore Biopharma Agrees to Go Private — 6-K · Nov 4, 2025 Risk: medium
  LakeShore Biopharma Co., Ltd. (formerly YS Biopharma Co., Ltd. and YishengBio Co., Ltd.) filed a 6-K report on November 4, 2025. The filing includes a press rel
• LakeShore Biopharma Transitions to OTC Market — 6-K · Sep 22, 2025 Risk: medium
  LakeShore Biopharma Co., Ltd. announced its transition to the OTC market, effective September 22, 2025. This move follows the company's previous name changes fr
• LakeShore Biopharma Faces Nasdaq Delisting — 6-K · Sep 12, 2025 Risk: high
  LakeShore Biopharma Co., Ltd. announced on September 12, 2025, that it received a determination from The Nasdaq Stock Market LLC indicating that the company's s
• LakeShore Biopharma Appoints New Independent Director — 6-K · Sep 10, 2025 Risk: low
  LakeShore Biopharma Co., Ltd. announced the appointment of Mr. Jianjun Liu as an independent director and a member of the audit committee, effective September 1
• LakeShore Biopharma Receives Revised Offer — 6-K · Aug 28, 2025 Risk: medium
  LakeShore Biopharma Co., Ltd. (formerly YS Biopharma Co., Ltd. and YishengBio Co., Ltd.) filed a 6-K report on August 28, 2025. The filing includes a press rele
• LakeShore Biopharma Files 6-K Amidst Preliminary Proposal — 6-K · Aug 18, 2025 Risk: medium
  LakeShore Biopharma Co., Ltd. (formerly YS Biopharma Co., Ltd. and YishengBio Co., Ltd.) filed a Form 6-K on August 18, 2025. The filing includes a press releas
• LakeShore Biopharma's Losses Widen Amid Revenue Dip, R&D Surge — 20-F · Jul 31, 2025 Risk: high
  LakeShore Biopharma Co., Ltd. (LSBWF) reported a net loss of $35.2 million for the fiscal year ended March 31, 2025, a significant increase from the $28.5 milli
• LakeShore Biopharma Reports Change in Control — 6-K · Jul 15, 2025 Risk: medium
  On July 8, 2025, LakeShore Biopharma Co., Ltd. reported a change in control. The company, formerly known as YS Biopharma Co., Ltd. and YishengBio Co., Ltd., is
• LakeShore Biopharma Files 6-K with Press Release — 6-K · Jul 8, 2025 Risk: low
  On July 8, 2025, LakeShore Biopharma Co., Ltd. (formerly YS Biopharma Co., Ltd. and YishengBio Co., Ltd.) issued a press release attached to its Form 6-K filing
• LakeShore Biopharma Director Resigns — 6-K · May 12, 2025 Risk: low
  LakeShore Biopharma Co., Ltd. announced on May 12, 2025, that Mr. Dave Chenn has resigned as a member of its board of directors. The company, formerly known as
• LakeShore Biopharma Enters Financing Lease Agreement — 6-K · May 6, 2025 Risk: low
  LakeShore Biopharma Co., Ltd. (formerly YS Biopharma Co., Ltd. and YishengBio Co., Ltd.) entered into a financing lease agreement through its subsidiary, Liaoni
• LakeShore Biopharma Wins Court Dismissal of Former Chairman's Injunctions — 6-K · Mar 25, 2025 Risk: medium
  LakeShore Biopharma Co., Ltd. announced on March 25, 2025, that a court has dismissed injunction applications filed by its former chairman. This dismissal is a
• LakeShore Biopharma Adopts Amended Share Incentive Plan — 6-K · Mar 12, 2025 Risk: low
  LakeShore Biopharma Co., Ltd. announced on March 12, 2025, the adoption of an Amended and Restated 2024 Share Incentive Plan. This plan aims to incentivize empl
• LakeShore Biopharma Files 6-K Report — 6-K · Dec 19, 2024 Risk: low
  LakeShore Biopharma Co., Ltd. (formerly YS Biopharma Co., Ltd. and YishengBio Co., Ltd.) filed a Form 6-K on December 19, 2024. The company, incorporated in E9
• LakeShore Biopharma Updates on Former Chairman's Criminal Probe — 6-K · Dec 12, 2024 Risk: medium
  LakeShore Biopharma Co., Ltd. (formerly YS Biopharma Co., Ltd. and YishengBio Co., Ltd.) filed a 6-K on December 12, 2024, to provide an update on an ongoing cr
• LakeShore Biopharma Changes Auditor to Grant Thornton — 6-K · Nov 12, 2024 Risk: low
  LakeShore Biopharma Co., Ltd. (formerly YS Biopharma Co., Ltd. and YishengBio Co., Ltd.) has filed a Form 6-K for November 2024. The company, located in Beijing
• LakeShore Biopharma Files 6-K Report — 6-K · Nov 7, 2024 Risk: low
  LakeShore Biopharma Co., Ltd. (formerly YS Biopharma Co., Ltd. and YishengBio Co., Ltd.) filed a Form 6-K on November 7, 2024. The filing is a report of a forei
• LakeShore Biopharma Announces Marketing Head Resignation — 6-K · Nov 1, 2024 Risk: medium
  LakeShore Biopharma Co., Ltd. announced the resignation of Mr. Gang Li, head of marketing and sales, effective October 31, 2024. The company, formerly known as
• LakeShore Biopharma Files 6-K Report — 6-K · Oct 29, 2024 Risk: low
  LakeShore Biopharma Co., Ltd. (formerly YS Biopharma Co., Ltd. and YishengBio Co., Ltd.) filed a Form 6-K on October 29, 2024. The filing is for the month of Oc
• LakeShore Biopharma Files 6-K Report — 6-K · Oct 25, 2024 Risk: low
  LakeShore Biopharma Co., Ltd. (formerly YS Biopharma Co., Ltd. and YishengBio Co., Ltd.) filed a Form 6-K on October 25, 2024. The filing is a report of a forei
• LakeShore Biopharma Files 6-K with FY2025 Half Year Results — 6-K · Oct 8, 2024 Risk: low
  LakeShore Biopharma Co., Ltd. (formerly YS Biopharma Co., Ltd. and YishengBio Co., Ltd.) filed a Form 6-K on October 8, 2024. The filing includes a press releas
• LakeShore Biopharma Holds Shareholder Meeting — 6-K · Sep 27, 2024 Risk: low
  LakeShore Biopharma Co., Ltd. (formerly YS Biopharma Co., Ltd. and YishengBio Co., Ltd.) filed a 6-K report on September 27, 2024. The filing pertains to the re
• LakeShore Biopharma Calls Extraordinary General Meeting — 6-K · Sep 10, 2024 Risk: low
  LakeShore Biopharma Co., Ltd. (formerly YS Biopharma Co., Ltd. and YishengBio Co., Ltd.) announced an Extraordinary General Meeting to be held in September 2024
• LakeShore Biopharma Files 6-K Report — 6-K · Sep 4, 2024 Risk: low
  LakeShore Biopharma Co., Ltd. (formerly YS Biopharma Co., Ltd. and YishengBio Co., Ltd.) filed a Form 6-K on September 4, 2024. The filing is a report of a fore
• LakeShore Biopharma Files 2024 Annual Report — 20-F · Aug 15, 2024 Risk: medium
  LakeShore Biopharma Co., Ltd. filed its annual report on Form 20-F for the fiscal year ended March 31, 2024. The company, formerly known as YS Biopharma Co., Lt
• LakeShore Biopharma Announces Extraordinary General Meeting — 6-K · Jul 5, 2024 Risk: low
  LakeShore Biopharma Co., Ltd. (formerly YS Biopharma Co., Ltd. and YishengBio Co., Ltd.) filed a 6-K report on July 5, 2024. The filing includes a press release
• LakeShore Biopharma Director Resigns — 6-K · Jun 18, 2024 Risk: low
  LakeShore Biopharma Co., Ltd. announced on June 18, 2024, that Ms. Chunyuan Wu (Brenda) has resigned from its board of directors. The company, formerly known as
• LakeShore Biopharma Directors Depart — 6-K · Jun 10, 2024 Risk: medium
  LakeShore Biopharma Co., Ltd. (formerly YS Biopharma Co., Ltd. and YishengBio Co., Ltd.) filed a Form 6-K on June 10, 2024. The filing indicates the departure o
• YS Biopharma Changes Name to LakeShore Biopharma — 6-K · May 24, 2024 Risk: low
  YS Biopharma Co., Ltd. announced a name change to LakeShore Biopharma, effective September 12, 2022. The company, previously known as YishengBio Co., Ltd., is a
• YS Biopharma Holds EGM, Approves All Resolutions — 6-K · May 21, 2024 Risk: low
  YS Biopharma Co., Ltd. announced the results of its Extraordinary General Meeting held on May 21, 2024. Shareholders approved all proposed resolutions, includin
• YS Biopharma to Hold Extraordinary General Meeting — 6-K · May 7, 2024 Risk: medium
  YS Biopharma Co., Ltd. announced on May 2, 2024, that its board of directors approved holding an extraordinary general meeting. The purpose of this meeting is t
• YS Biopharma Gets 180-Day Nasdaq Bid Price Extension — 6-K · Apr 29, 2024 Risk: medium
  YS Biopharma Co., Ltd. announced on April 29, 2024, that it has received an additional 180-day extension from Nasdaq to regain compliance with the minimum bid p
• YS Biopharma Files 6-K with FY2024 Nine-Month Financials — 6-K · Apr 19, 2024 Risk: medium
  YS Biopharma Co., Ltd. filed a Form 6-K on April 19, 2024, to report its unaudited financial results for the first nine months of its fiscal year 2024. The fili
• YS Biopharma Gets Phase I License for Hep B Vaccine — 6-K · Apr 18, 2024 Risk: medium
  YS Biopharma Co., Ltd. announced on April 18, 2024, that it has been granted a Phase I clinical trial license for its therapeutic chronic Hepatitis B Virus (HBV
• YS Biopharma's PIKA Rabies Vaccine Shows Positive Phase 3 Results — 6-K · Apr 9, 2024 Risk: medium
  YS Biopharma Co., Ltd. announced positive interim results on April 9, 2024, for its pivotal Phase 3 clinical study of the PIKA Rabies Vaccine. The study, conduc
• YS Biopharma Repays $40M Loan — 6-K · Apr 3, 2024 Risk: low
  YS Biopharma Co., Ltd. announced on April 3, 2024, the full repayment of its US$40,000,000 loan facility. This repayment was made using funds from the company's
• YS Biopharma Announces Leadership Changes — 6-K · Mar 5, 2024 Risk: low
  YS Biopharma Co., Ltd. announced board changes and strategic leadership appointments in its Chinese subsidiaries on March 5, 2024. The company, formerly known a
• YS Biopharma Updates Share Ownership, Confirms Foreign Issuer Status — 6-K · Feb 23, 2024 Risk: low
  YS Biopharma Co., Ltd. (Nasdaq: YS) filed a 6-K on February 23, 2024, to provide an update on the beneficial ownership of its shares. The filing indicates that
• YS Biopharma Holds EGM, Discloses Results in 6-K Filing — 6-K · Feb 22, 2024 Risk: low
  YS Biopharma Co., Ltd. (NASDAQ: YS) announced the results of its Extraordinary General Meeting held on February 22, 2024. The company, a foreign private issuer,
• YS Biopharma Holds EGM, Addresses False Statements — 6-K · Feb 20, 2024 Risk: medium
  YS Biopharma Co., Ltd. (NASDAQ: YS) announced the results of its Extraordinary General Meeting held on February 16, 2024, and addressed what it described as fal
• SC 13G/A Filing — SC 13G/A · Feb 16, 2024
• SC 13G Filing — SC 13G · Feb 15, 2024
• YS Biopharma Reports Director Removal in February 6-K Filing — 6-K · Feb 14, 2024 Risk: medium
  YS Biopharma Co., Ltd. (Nasdaq: YS) filed a Form 6-K on February 14, 2024, reporting a director removal. This filing indicates a change in the company's board s
• YS Biopharma Secures $40M Private Placement, Issues 95.2M Shares — 6-K · Feb 9, 2024 Risk: medium
  YS Biopharma Co., Ltd. announced on February 9, 2024, a private placement of 95,269,762 ordinary shares to an institutional investor for US$40 million. The shar
• YS Biopharma Subsidiary Notified of Loan Default by R-Bridge — 6-K · Jan 26, 2024
  YS Biopharma Co., Ltd. (YS Biopharma) disclosed on January 23, 2024, that its subsidiary, YishengBio (Hong Kong) Holdings Limited (Yisheng HK), received a lette
• YS Biopharma Reports Unaudited H1 FY24 Financial Results — 6-K · Jan 22, 2024
  YS Biopharma Co., Ltd. (NASDAQ: YS) announced its unaudited consolidated financial results for the first half of fiscal year 2024, which ended on March 31, 2024
• YS Biopharma Appoints Rui Yu as Audit Committee Chairperson — 6-K · Jan 8, 2024
  YS Biopharma Co., Ltd. (NASDAQ: YS) announced on January 8, 2024, that its Board of Directors appointed Ms. Rui Yu as the new Chairperson of the Audit Committee

Risk Profile

Risk Assessment: Of LSBWF's 42 recent filings, 2 were flagged as high-risk, 18 as medium-risk, and 22 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Key Executives

• Jianjun Liu
• Xu Wang
• Dave Chenn
• Gang Li
• Ms. Chunyuan Wu (Brenda)
• Dr. Ajit Shetty
• Dr. Viren Mehta
• Mr. Haitao Zhao
• Mr. Henry Chen
• Mr. Pierson Yue Pan
• institutional investor

Industry Context

The pharmaceutical preparations industry, particularly the vaccine segment, is characterized by high R&D investment, long development cycles, and stringent regulatory oversight. Companies like LakeShore Biopharma compete on innovation, clinical trial success, and the ability to navigate complex global regulatory landscapes. The market is driven by demand for preventative healthcare and the emergence of new infectious diseases.

Top Tags

foreign-private-issuer (9) · corporate-action (8) · corporate-governance (8) · foreign-issuer (5) · 6-K (5) · regulatory-filing (5) · press-release (4) · company-name-change (4) · filing (4) · biopharma (4)

Key Numbers

• SEC File Number: 001-41598 — Identifies the specific SEC filing for LakeShore Biopharma
• Net Loss: $35.2M — Increased from $28.5M in prior year, indicating worsening profitability for fiscal year ended March 31, 2025.
• Revenue: $12.8M — Decreased 15% from $15.1M in prior year, primarily due to reduced YSJA™ rabies vaccine sales.
• Research and Development Expenses: $22.5M — Increased 10% year-over-year, reflecting focus on PIKA® rabies vaccine and immunology candidates.
• Ordinary Shares Outstanding: 20,766,531 — As of March 31, 2025, indicating the company's share count.
• Proceeds from Divestiture: $5.0M — Generated from the strategic divestiture of its non-core diagnostic division in Q3 2025.
• Commission File Number: 001-41598 — Identifies the specific SEC filing series for the company.
• Fiscal Year End: 0331 — Indicates the end of the reporting period for financial statements.
• Central Index Key: 0001946399 — Unique identifier for the company in SEC filings.
• Extension Period: 180 days — Additional time granted by Nasdaq
• Minimum Bid Price: $1.00 — Required closing bid price for compliance
• Compliance Deadline: October 21, 2024 — New date by which compliance must be achieved
• Fiscal Year: FY2024 — Reporting period for the financial results
• Loan Facility Repayment: $40.0B — YS Biopharma fully repaid its US$40,000,000 loan facility using operating cash flow.
• Private Placement Value: $40 million — Total capital raised by YS Biopharma

Forward-Looking Statements

• {"claim":"YS Biopharma's stock price may experience short-term volatility due to the dilution effect.","entity":"YS Biopharma Co., Ltd.","targetDate":"Q1 2024","confidence":"medium"}
• {"claim":"The US$40 million capital infusion will be primarily used to fund ongoing research and development projects.","entity":"YS Biopharma Co., Ltd.","targetDate":"Q2 2024","confidence":"low"}

Related Companies

LSB · LSBPW · LAKESHORE · YS

Frequently Asked Questions